It is clear that the influence of miRNA-486 levels in response to treatment appears to be tissue-dependent, with potential for NSCLC and breast tumors to be sensitised to a range of treatments, with the caveat that ALK-translocated NSCLC experience the opposite effect, becoming more resistant to treatment. This evidence concerns the gene ALK and breast neoplasm.